Literature DB >> 17391724

Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro.

Manisha Gupta1, Christina Spiropoulou, Pierre E Rollin.   

Abstract

Ebola virus causes an often fatal disease characterized by poor immune response and high inflammatory reaction in the patients. One of the causes for poor immunity is virus-mediated apoptosis of lymphocytes in the host. In this study, we infected human PBMCs with Ebola Zaire virus and study apoptosis of different cell types using flow cytometry. We have shown that Ebola virus causes bystander death of CD4 and CD8 T cells. Cells infected with virus had 30-40% active caspase 3(+), annexin-V(+) and Bcl2(low) phenotype by day 8 PI as compared to inactivated virus-treated cells. 60-70% of the macrophages were also dead by day 8 PI and had similar phenotype. Our data also showed that virus may induce death signals in Fas(+)/FasL(+) T lymphocytes and macrophages but did not upregulate Fas/FasL expression in these cells. Lastly, CD4, CD8 and CD14 cells were purified after infection and were studied for death signals by RNAse protection assay. We found an upregulation of TRAIL mRNA in CD4 and CD8 T cells on day 7 PI. A two-fold increase in CD4 T cells and three-fold increase in CD8 T cells were observed in TRAIL mRNA levels as compared to uninfected controls and inactive virus-treated cells. Surprisingly, we did not find any difference in TRAIL mRNA levels between infected macrophages and uninfected controls. These data suggest that Ebola virus evades the immune response by causing massive lymphocyte death. In addition, they may give an explanation on why the host is unable to produce a good antibody response in the absence of CD4 T cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391724     DOI: 10.1016/j.virol.2007.02.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  54 in total

1.  Clinical aspects of Marburg hemorrhagic fever.

Authors:  Masfique Mehedi; Allison Groseth; Heinz Feldmann; Hideki Ebihara
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

2.  Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread.

Authors:  Kristina Maria Schmidt; Michael Schümann; Judith Olejnik; Verena Krähling; Elke Mühlberger
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

3.  Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.

Authors:  Kathleen C Prins; Jennifer M Binning; Reed S Shabman; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

4.  Ebola virus and persistent chronic infection: when does replication cease?

Authors:  John V Forrester
Journal:  Ann Transl Med       Date:  2018-11

Review 5.  Rationale for Adjunctive Therapies for Pediatric Sepsis Induced Multiple Organ Failure.

Authors:  Bradley S Podd; Dennis W Simon; Santiago Lopez; Andrew Nowalk; Rajesh Aneja; Joseph A Carcillo
Journal:  Pediatr Clin North Am       Date:  2017-08-18       Impact factor: 3.278

Review 6.  Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.

Authors:  Ilhem Messaoudi; Gaya K Amarasinghe; Christopher F Basler
Journal:  Nat Rev Microbiol       Date:  2015-10-06       Impact factor: 60.633

7.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

8.  The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains.

Authors:  Ndongala M Lubaki; Philipp Ilinykh; Colette Pietzsch; Bersabeh Tigabu; Alexander N Freiberg; Richard A Koup; Alexander Bukreyev
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

9.  Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Authors:  Nadia Wauquier; Pierre Becquart; Cindy Padilla; Sylvain Baize; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

10.  Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein.

Authors:  Amy L Hartman; Ling Ling; Stuart T Nichol; Martin L Hibberd
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.